These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21321137)

  • 1. Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.
    Shima K; Szaszák M; Solbach W; Gieffers J; Rupp J
    Antimicrob Agents Chemother; 2011 May; 55(5):2319-24. PubMed ID: 21321137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
    Donati M; Rodrìguez Fermepin M; Olmo A; D'Apote L; Cevenini R
    J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia.
    Shima K; Klinger M; Solbach W; Rupp J
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2828-30. PubMed ID: 23478971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.
    Donati M; Di Francesco A; D'Antuono A; Delucca F; Shurdhi A; Moroni A; Baldelli R; Cevenini R
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5379-80. PubMed ID: 20855744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fluoroquinolones, azithromycin and doxycycline against chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms.
    Smelov V; Perekalina T; Gorelov A; Smelova N; Artemenko N; Norman L
    Eur Urol; 2004 Nov; 46(5):647-50. PubMed ID: 15474277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis.
    Bébéar CM; de Barbeyrac B; Pereyre S; Renaudin H; Clerc M; Bébéar C
    Clin Microbiol Infect; 2008 Aug; 14(8):801-5. PubMed ID: 18727805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.
    Lea AP; Lamb HM
    Pharmacoeconomics; 1997 Nov; 12(5):596-611. PubMed ID: 10174326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells.
    Foschi C; Salvo M; Cevenini R; Marangoni A
    J Antimicrob Chemother; 2018 Feb; 73(2):409-413. PubMed ID: 29077843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate.
    Ljubin-Sternak S; Mestrovic T; Vilibic-Cavlek T; Mlinaric-Galinovic G; Sviben M; Markotic A; Skerk V
    Folia Microbiol (Praha); 2013 Sep; 58(5):361-5. PubMed ID: 23271498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
    Carryn S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2095-103. PubMed ID: 12069960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.
    Agacfidan A; Moncada J; Schachter J
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1746-8. PubMed ID: 8239579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
    Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
    Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.
    Dreses-Werringloer U; Padubrin I; Zeidler H; Köhler L
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3001-8. PubMed ID: 11600348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections.
    Pitt R; Alexander S; Ison C; Horner P; Hathorn E; Goold P; Woodford N; Cole MJ
    J Antimicrob Chemother; 2018 Mar; 73(3):680-686. PubMed ID: 29207004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing effects of azithromycin and doxycycline on cytokines in cells from Chlamydia trachomatis-infected women.
    Srivastava P; Bhengraj AR; Jha HC; Vardhan H; Jha R; Singh LC; Salhan S; Mittal A
    DNA Cell Biol; 2012 Mar; 31(3):392-401. PubMed ID: 21848430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host immune responses after hypoxic reactivation of IFN-γ induced persistent Chlamydia trachomatis infection.
    Jerchel S; Kaufhold I; Schuchardt L; Shima K; Rupp J
    Front Cell Infect Microbiol; 2014; 4():43. PubMed ID: 24783060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India.
    Bhengraj AR; Vardhan H; Srivastava P; Salhan S; Mittal A
    Chemotherapy; 2010; 56(5):371-7. PubMed ID: 20938174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection.
    Shao L; You C; Cao J; Jiang Y; Liu Y; Liu Q
    Int J Infect Dis; 2020 Jul; 96():121-127. PubMed ID: 32173573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents.
    Zhang Y; Xian Y; Gao L; Elaasar H; Wang Y; Tauhid L; Hua Z; Shen L
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
    Kohlhoff SA; Huband MD; Hammerschlag MR
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.